Philipp Erben
- Hematology top 0.5%
- Chronic Myeloid Leukemia Treatments 55
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research 39
- Myeloproliferative Neoplasms: Diagnosis and Treatment 14
- Rheumatology top 0.5%
- Eosinophilic Disorders and Syndromes 46
- Cancer Research top 5%
- Oncology top 5%
-
- Bladder and Urothelial Cancer Treatments 54
- Urinary and Genital Oncology Studies 42
-
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 9
- Ferroptosis and cancer prognosis 9
- Co-authors
- Andreas HochhausMartin C. MüllerThomas ErnstJörge E. CortesSusan BranfordGiuseppe SaglioDong‐Wook KimNicholas C.P. Cross
- Cited by
- HematologyGeneticsRheumatology
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Philipp Erben
157 papers receiving 3.7k citations
Peers
Comparison fields: 5 of 96
- Hematology 2.0k
- Genetics 1.8k
- Rheumatology 1.5k
- Cancer Research 355
- Oncology 640
Countries citing papers authored by Philipp Erben
This map shows the geographic impact of Philipp Erben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philipp Erben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philipp Erben more than expected).
Fields of papers citing papers by Philipp Erben
This network shows the impact of papers produced by Philipp Erben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philipp Erben. The network helps show where Philipp Erben may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Philipp Erben, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2023 | 4 | |
| 3 | 2023 | 4 | |
| 4 | 2021 | 12 | |
| 5 | 2021 | 5 | |
| 6 | 2020 | 6 | |
| 7 | 2020 | 1 | |
| 8 | 2020 | 5 | |
| 9 | 2019 | 15 | |
| 10 | 2019 | 58 | |
| 11 | 2019 | 17 | |
| 12 | 2018 | 8 | |
| 13 | 2016 | 27 | |
| 14 | 2016 | 16 | |
| 15 | 2010 | 120 | |
| 16 | Downstream effectors of FIP1L1-PDGFRA as targets for therapy in chronic eosinophilic leukemia | 2010 | 1 |
| 17 | 2009 | 236 | |
| 18 | 2009 | 56 | |
| 19 | 2007 | 64 | |
| 20 | 2006 | 3 |
About Philipp Erben
Philipp Erben is a scholar working on Hematology, Genetics, Rheumatology, Urology and Surgery, having authored 161 papers that have together received 3.8k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (55 papers), Bladder and Urothelial Cancer Treatments (54 papers), Eosinophilic Disorders and Syndromes (46 papers), Urinary and Genital Oncology Studies (42 papers), Chronic Lymphocytic Leukemia Research (39 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers) and Ferroptosis and cancer prognosis (9 papers). The work is most often cited by research in Hematology (2.0k citations), Genetics (1.8k citations), Rheumatology (1.5k citations), Cancer Research (355 citations) and Oncology (640 citations). Philipp Erben has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Andreas Hochhaus, Martin C. Müller, Thomas Ernst, Jörge E. Cortes, Susan Branford, Giuseppe Saglio, Dong‐Wook Kim, Nicholas C.P. Cross, Rüdiger Hehlmann and Andreas Reiter. Their work appears in journals such as Blood, Journal of Clinical Oncology, Haematologica, Leukemia and Journal of Cancer Research and Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.